NEW YORK (GenomeWeb) – Luxembourg's Advanced Biological Laboratories (ABL) announced Tuesday that it has signed an agreement granting Thermo Fisher Scientific international distribution rights for ABL's ViroScore Suite and DeepChek virology sequencing analysis software.
Under the terms of the agreement, Thermo Fisher has the rights to distribute the software around the world, excluding Spain, China, and Japan.
Financial and other details were not disclosed.
"The excellent performances of our ViroScore and DeepChek downstream analysis software, which are ideally suited for lab automation, will be further enhanced through this distribution agreement," ABL CEO Chalom Sayada said in a statement. "This comprehensive end-to-end solution is ideal for laboratories who seek to consolidate their operations, while enhancing the quality of their results."
ViroScore and DeepCheck offer analysis for Sanger and next-generation sequencing, respectively, and are compatible with Applied Biosystems genetic analysis and Ion Torrent NGS systems. The software is available through the Thermo Fisher Cloud.
Using the programs, laboratories can track viral populations, identify changes within genomes, and recognize dual infections and co-infection, the firm said. Its products are for research use only in the US.
ABL is a spinoff of the Luxembourg Institute of Health, formerly known as CRP-Santé. The firm also offers virology reagents, including the DeepChek SingleRound Genotyping and Sequencing assays for HIV and hepatitis C virus. It has in the past signed promotional agreements with Roche and Abbott.